SORBITOL-MANNITOL IN PLASTIC CONTAINER

Clinical safety rating: safe

Other diuretics may have additive effects Can cause fluid and electrolyte imbalances and pulmonary congestion.

How it works

Sorbitol and mannitol are osmotic diuretics. They increase osmotic pressure in the glomerular filtrate, reducing water reabsorption and promoting diuresis. Mannitol also decreases intracranial and intraocular pressure by creating an osmotic gradient that draws water from tissues into the vasculature.

What the body does with it

Metabolism	Sorbitol is metabolized in the liver to fructose via sorbitol dehydrogenase; mannitol is minimally metabolized and is excreted unchanged by the kidneys.
Excretion	Renal: >95% as unchanged sorbitol and mannitol; negligible biliary/fecal elimination.
Half-life	Sorbitol: approximately 0.5-1 hour; mannitol: approximately 0.5-1.5 hours. In anuria, mannitol half-life may extend to 36 hours.
Protein binding	Negligible (<1%), no specific binding proteins.
Volume of Distribution	Sorbitol: ~0.3 L/kg; mannitol: ~0.2-0.3 L/kg; distributes primarily into extracellular fluid.
Bioavailability	Oral: 10-30% (sorbitol) due to incomplete absorption; mannitol oral absorption ~10-20%. IV: 100%.
Onset of Action	Oral: 30-60 minutes for cathartic effect; IV: minutes for osmotic diuresis.
Duration of Action	Oral: 1-2 hours for cathartic effect; IV: 1-3 hours for diuretic effect, depending on renal function.

Classification & Brands

Dosing & administration

Intravenous infusion of 50 mL of a 25% sorbitol-25% mannitol solution administered over 10–20 minutes; may repeat once after 6–8 hours if needed.

Dosage form	SOLUTION
Renal impairment	Contraindicated in anuria or severe renal impairment (eGFR < 30 mL/min/1.73 m²). For eGFR 30–59 mL/min/1.73 m², extend dosing interval to every 12–24 hours and monitor serum osmolarity. No adjustment for eGFR ≥ 60.
Liver impairment	No dose adjustment required for Child-Pugh Class A or B. For Class C, use with caution and monitor for encephalopathy; consider reducing dose by 50%.
Pediatric use	Children: 2 mL/kg of 25% sorbitol-mannitol solution intravenously over 20–30 minutes; may repeat once after 8 hours. Maximum dose not to exceed 50 mL total.
Geriatric use	Initiate at lower end of dosing range (25–50 mL) due to increased risk of renal impairment and electrolyte disturbances. Monitor renal function and fluid status closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Other diuretics may have additive effects Can cause fluid and electrolyte imbalances and pulmonary congestion.

FDA category	Animal
Breastfeeding	Excretion in human milk unknown; M/P ratio not established. Use caution due to risk of osmotic diarrhea and electrolyte imbalance in infant.
Teratogenic Risk	No teratogenic effects reported; insufficient data to assess risk in first trimester. Osmotic diuretics cross placenta; may cause electrolyte imbalance in fetus. Avoid in third trimester due to risk of fetal dehydration and electrolyte disturbances.

Warnings & precautions

■ FDA Black Box Warning

WARNING: Sorbitol-mannitol solution may cause severe electrolyte disturbances, including hyponatremia and hyperkalemia. Monitor serum electrolytes, renal function, and fluid balance closely. Use with caution in patients with renal impairment or congestive heart failure. Rapid administration can cause volume overload and pulmonary edema.

Side Effect Profile

Common Effects	edema
Serious Effects

Absolute Contraindications

Anuria, severe renal disease, severe dehydration, active intracranial bleeding (except during craniotomy), known hypersensitivity to sorbitol or mannitol, and severe pulmonary congestion or edema.

Clinical Precautions

Precautions

Monitor for electrolyte imbalances, fluid overload, and renal function. Use cautiously in patients with cardiac disease, renal impairment, or pulmonary congestion. Avoid extravasation due to risk of tissue necrosis. Contraindicated in anuria or severe renal disease.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

SORBITOL-MANNITOL IN PLASTIC CONTAINER

Clinical safety rating: safe

Other diuretics may have additive effects Can cause fluid and electrolyte imbalances and pulmonary congestion.

How it works

What the body does with it

Metabolism	Sorbitol is metabolized in the liver to fructose via sorbitol dehydrogenase; mannitol is minimally metabolized and is excreted unchanged by the kidneys.
Excretion	Renal: >95% as unchanged sorbitol and mannitol; negligible biliary/fecal elimination.
Half-life	Sorbitol: approximately 0.5-1 hour; mannitol: approximately 0.5-1.5 hours. In anuria, mannitol half-life may extend to 36 hours.
Protein binding	Negligible (<1%), no specific binding proteins.
Volume of Distribution	Sorbitol: ~0.3 L/kg; mannitol: ~0.2-0.3 L/kg; distributes primarily into extracellular fluid.
Bioavailability	Oral: 10-30% (sorbitol) due to incomplete absorption; mannitol oral absorption ~10-20%. IV: 100%.
Onset of Action	Oral: 30-60 minutes for cathartic effect; IV: minutes for osmotic diuresis.
Duration of Action	Oral: 1-2 hours for cathartic effect; IV: 1-3 hours for diuretic effect, depending on renal function.

Classification & Brands

Dosing & administration

Intravenous infusion of 50 mL of a 25% sorbitol-25% mannitol solution administered over 10–20 minutes; may repeat once after 6–8 hours if needed.

Dosage form	SOLUTION
Renal impairment	Contraindicated in anuria or severe renal impairment (eGFR < 30 mL/min/1.73 m²). For eGFR 30–59 mL/min/1.73 m², extend dosing interval to every 12–24 hours and monitor serum osmolarity. No adjustment for eGFR ≥ 60.
Liver impairment	No dose adjustment required for Child-Pugh Class A or B. For Class C, use with caution and monitor for encephalopathy; consider reducing dose by 50%.
Pediatric use	Children: 2 mL/kg of 25% sorbitol-mannitol solution intravenously over 20–30 minutes; may repeat once after 8 hours. Maximum dose not to exceed 50 mL total.
Geriatric use	Initiate at lower end of dosing range (25–50 mL) due to increased risk of renal impairment and electrolyte disturbances. Monitor renal function and fluid status closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Other diuretics may have additive effects Can cause fluid and electrolyte imbalances and pulmonary congestion.

FDA category	Animal
Breastfeeding	Excretion in human milk unknown; M/P ratio not established. Use caution due to risk of osmotic diarrhea and electrolyte imbalance in infant.
Teratogenic Risk	No teratogenic effects reported; insufficient data to assess risk in first trimester. Osmotic diuretics cross placenta; may cause electrolyte imbalance in fetus. Avoid in third trimester due to risk of fetal dehydration and electrolyte disturbances.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Common Effects	edema
Serious Effects

Absolute Contraindications

Anuria, severe renal disease, severe dehydration, active intracranial bleeding (except during craniotomy), known hypersensitivity to sorbitol or mannitol, and severe pulmonary congestion or edema.